MacroGenics sells GMP manufacturing operations to Bora for $122.5 million

MacroGenics, Inc.

MacroGenics, Inc.

MGNX

0.00
  • MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for USD 122.5 million, subject to post-closing adjustments.
  • Bora assumed responsibility for manufacturing supporting clinical and commercial production.
  • The Rockville, Maryland manufacturing site, Frederick, Maryland warehouse transferred to Bora; about 140 former employees moved to Bora.
  • A supply agreement covers process development, drug substance production for MacroGenics’ pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020925PRIMZONEFULLFEED9756175) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.